Valuation: Spyre Therapeutics, Inc.

Market Cap 9.06B 7.85B 7.35B 6.71B 12.61B 864B 12.8B 86.49B 33.81B 433B 34.01B 33.27B 1,443B P/E 2026 *
-35.6x
P/E 2027 * -29x
Enterprise Value 8.6B 7.45B 6.98B 6.37B 11.98B 821B 12.16B 82.14B 32.11B 411B 32.3B 31.6B 1,370B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
89.36%
Yield 2026 *
-
Yield 2027 * -
1 day-0.82%
1 week-3.85%
Current month-1.13%
1 month+2.94%
3 months+36.72%
6 months+208.10%
Current year+219.34%
1 week 87.5
Extreme 87.5
91
1 month 81.5
Extreme 81.5
91
Current year 25.4
Extreme 25.4
91
1 year 12.3
Extreme 12.3
91
3 years 10.3
Extreme 10.3
91
5 years 10.3
Extreme 10.3
91
10 years 10.3
Extreme 10.3
91
Manager TitleAgeSince
Chief Executive Officer 36 2023-11-26
Director of Finance/CFO 49 2023-08-31
Chief Tech/Sci/R&D Officer - 2023-11-26
Director TitleAgeSince
Director/Board Member 36 2023-11-26
Director/Board Member 39 2023-06-21
Director/Board Member 36 2023-06-21
Change 5-day change 1-year change 3-year change Capi.($)
-0.82%-3.85% - - 9.06B
-0.73%+12.52%+74.33%+102.34% 70.51B
+1.60%+1.66%+37.76%+66.48% 54.05B
+1.38%+35.83%+10.24%+503.12% 28.95B
-0.61%+12.95%+53.77%+5.42% 24.05B
+0.50%+1.48%-15.73%-12.94% 23.31B
-1.37%+18.52%+255.24%+464.53% 18.67B
+2.21%+7.66%+47.18%-19.64% 18.37B
0.00%+9.69%+31.01%+584.59% 16.1B
+0.11%-9.33%+35.47%+139.01% 12.72B
Average +0.22%+9.21%+58.81%+203.66% 29.64B
Weighted average by Cap. +0.28%+10.12%+56.56%+167.57%

Financials

2026 *2027 *
Net sales - -
Net income -258M -224M -210M -191M -359M -24.63B -365M -2.47B -964M -12.33B -969M -948M -41.12B -327M -283M -265M -242M -455M -31.16B -462M -3.12B -1.22B -15.6B -1.23B -1.2B -52.03B
Net Debt -456M -395M -370M -337M -634M -43.46B -644M -4.35B -1.7B -21.76B -1.71B -1.67B -72.55B -565M -490M -459M -418M -787M -53.89B -799M -5.39B -2.11B -26.99B -2.12B -2.08B -89.98B
Logo Spyre Therapeutics, Inc.
Spyre Therapeutics, Inc. is a clinical-stage biotechnology company, specializing in long-acting antibodies and antibody combinations for inflammatory bowel disease (IBD) and rheumatic diseases. The Company's pipeline includes investigational extended half-life antibodies targeting a4b7, TL1A, and IL-23. It is advancing a pipeline of monoclonal antibodies (mAbs) for the treatment of IBD and other immune-mediated diseases. The Company's pipeline includes its SKYLINE Phase II platform trial evaluating SPY001, SPY002, SPY003, and pairwise combinations thereof in subjects with moderately to severely active UC and its SKYWAY basket trial evaluating SPY072 in three rheumatic diseases: rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA). SPY001 is a highly potent, highly selective, and humanized monoclonal immunoglobulin G1 investigational antibody designed to bind selectively to the a4b7 integrin being developed for the treatment of IBD (UC and CD).
Employees
125
Date Price Change
26-08-12 87.50 -3.85%
26-08-11 €91.00 0.00%
26-08-10 €91.00 +1.11%
26-08-07 €90.00 0.00%
26-08-06 €90.00 -1.10%
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
102.74USD
Average target price
122.14USD
Spread / Average Target
+18.89%

Quarterly revenue - Rate of surprise